Tauriga Sciences, Inc. Appoints Colorado-based Orthopedic Surgeon, Dr. Craig Loucks, as Member of the Company’s Advisory Board

Tauriga Sciences mg Magazine mg retailler

NEW YORK, NY – Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a New York based diversified Life Sciences Company, today announced the appointment of Dr. Craig Loucks (“Dr. Loucks”) as a member of the Company’s Advisory Board. Dr. Loucks is an accomplished orthopedic surgeon, based in Englewood, Colorado. Dr. Loucks is a strong believer in Cannabidiol (“CBD”) based products and has pre-ordered the Company’s enhanced 25mg CBD and CBG infused Tauri-Gum™ products. Dr. Loucks will mainly assist the Company in generating Tauri-Gum™ product sales, from both Medical Practices and Dispensaries. He will also provide his expertise to the Company, with respect to its ongoing Pharmaceutical development efforts.

Link to Personal Bio – Craig Loucks, MD: https://www.peakorthopedics.com/craig-loucks-peak-orthopedics-spine.html


Dr. Craig Loucks stated, “I am both pleased and excited to join Tauriga Sciences, Inc. as a member of the Company’s advisory board.  The Tauri-Gum™ product line is of outstanding quality and incorporates sublingual absorption delivery method.  There is a significant opportunity for Tauriga to market this product line to both medical practices and dispensaries throughout the state of Colorado.  I look forward to working closely with Tauriga’s management team as well as its Chief Medical Officer.”


Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives.  The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment.  The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant), (Vitamin C + Zinc Infused Tauri-Gum™ Flavor: Pear Bellini), (Caffeine Infused Tauri-Gum™ Flavor: Cherry Lime Rickey), & (Vitamin D3 Infused Tauri-Gum™ Flavor: Golden Raspberry).  The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at http://www.tauriga.com

Complementary to the Company’s retail business, is its ongoing Pharmaceutical Development initiative.  This relates to the development of a proposed Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed for the following indication: Patients Subjected to Ongoing Chemotherapy Treatment). On March 22, 2021, the Company announced that it had Converted its U.S. Provisional Patent Application (filed on March 17, 2020) into a U.S. Non-Provisional Patent Application.  The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”.  On December 18, 2020 the Company disclosed that it had entered into a Master Services Agreement with CSTI to lead the Company’s clinical development efforts.

The Company is headquartered in Wappingers Falls, New York.  In addition, the Company operates two full time E-Commerce fulfillment centers: one located in Montgomery, Texas and the other in Brooklyn, New York.